{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T01:03:36Z","timestamp":1791594216077,"version":"4.3.4"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T00:00:00Z","timestamp":1613520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["1805518N"],"award-info":[{"award-number":["1805518N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["1S23017N"],"award-info":[{"award-number":["1S23017N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["C12\/16\/024"],"award-info":[{"award-number":["C12\/16\/024"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004727","name":"Vlaams Instituut voor Biotechnologie","doi-asserted-by":"publisher","award":["GC01-C01"],"award-info":[{"award-number":["GC01-C01"]}],"id":[{"id":"10.13039\/501100004727","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>STAT1 gain-of-function (GOF) is a primary immunodeficiency typically characterized by chronic mucocutaneous candidiasis (CMC), recurrent respiratory infections, and autoimmunity. Less commonly, also immunodysregulation polyendocrinopathy enteropathy X-linked (IPEX)-like syndromes with CMC, and combined immunodeficiency without CMC have been described. Recently, our group and others have shown that different mutation-specific mechanisms underlie STAT1 GOF <jats:italic>in vitro<\/jats:italic>, including faster nuclear accumulation (R274W), and reduced mobility (R321, N574I) to near immobility in the nucleus (T419R) upon IFN\u03b3 stimulation. In this work, we evaluated the transcriptomic fingerprint of the aforementioned STAT1 GOF mutants (R274W, R321S, T419R, and N574I) relative to STAT1 wild-type upon IFN\u03b3 stimulation in an otherwise isogenic cell model. The majority of genes up-regulated in wild-type STAT1 cells were significantly more up-regulated in cells expressing GOF mutants, except for T419R. In addition to the common interferon regulated genes (IRG), STAT1 GOF mutants up-regulated an additional set of genes, that were in part shared with other GOF mutants or mutation-specific. Overall, R274W and R321S transcriptomes clustered with STAT1 WT, while T419R and N574I had a more distinct fingerprint. We observed reduced frequency of canonical IFN\u03b3 activation site (GAS) sequences in promoters of genes up-regulated by all the STAT1 GOF mutants, suggesting loss of DNA binding specificity for the canonical GAS consensus. Interestingly, the T419R mutation, expected to directly increase the affinity for DNA, showed the most pronounced effects on the transcriptome. T419R STAT1 dysregulated more non-IRG than the other GOF mutants and fewer GAS or degenerate GAS promotor sequences could be found in the promoter regions of these genes. In conclusion, our work confirms hyperactivation of common sets of IFN\u03b3-induced genes in STAT1 GOF with additional dysregulation of mutation-specific genes, in line with the earlier observed mutation-specific mechanisms. Binding to more degenerate GAS sequences is proposed as a mechanism toward transcriptional dysregulation in R274W, R321S, and N574I. For T419R, an increased interaction with the DNA is suggested to result in a broader and less GAS-specific response. Our work indicates that multiple routes leading to STAT1 GOF are associated with common and private transcriptomic fingerprints, which may contribute to the phenotypic variation observed <jats:italic>in vivo<\/jats:italic>.<\/jats:p>","DOI":"10.3389\/fimmu.2021.632997","type":"journal-article","created":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T20:21:48Z","timestamp":1613766108000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["Transcriptional Profiling of STAT1 Gain-of-Function Reveals Common and Mutation-Specific Fingerprints"],"prefix":"10.3389","volume":"12","author":[{"given":"Simone","family":"Giovannozzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Demeulemeester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rik","family":"Schrijvers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rik","family":"Gijsbers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,2,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1084\/jem.20110958","article-title":"Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis","volume":"208","author":"Liu","year":"2011","journal-title":"J Exp Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1056\/NEJMoa1100102","article-title":"STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis","volume":"365","author":"van","year":"2011","journal-title":"N Engl J Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1007\/s10875-020-00847-x","article-title":"Human STAT1 gain-of-function heterozygous mutations: chronic mucocutaneous candidiasis and type I interferonopathy","volume":"40","author":"Okada","year":"2020","journal-title":"J Clin Immunol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"3154","DOI":"10.1182\/blood-2015-11-679902","article-title":"Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype","volume":"127","author":"Toubiana","year":"2016","journal-title":"Blood."},{"key":"B5","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1093\/cid\/civ1220","article-title":"Progressive multifocal leukoencephalopathy in primary immune deficiencies: STAT1 gain of function and review of the literature","volume":"62","author":"Zerbe","year":"2016","journal-title":"Clin Infect Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1016\/j.jaci.2012.11.054","article-title":"Dominant gain-of-function STAT1 mutations in FOXP3WT IPEX-like Syndrome","volume":"131","author":"Uzel","year":"2013","journal-title":"J Allergy Clin Immunol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"325","DOI":"10.3899\/jrheum.180210","article-title":"An adult fatal case with a STAT1 gain-of-function mutation associated with multiple autoimmune diseases","volume":"46","author":"Maeshima","year":"2019","journal-title":"J Rheumatol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1007\/s10875-014-0111-7","article-title":"Orf infection in a patient with Stat1 gain-of-function","volume":"35","author":"Kilic","year":"2015","journal-title":"J Clin Immunol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s10875-018-0554-3","article-title":"Novel STAT1 gain-of-function mutation presenting as combined immunodeficiency","volume":"38","author":"Hartono","year":"2018","journal-title":"J Clin Immunol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/j.jaci.2018.07.020","article-title":"Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations","volume":"142","author":"Forbes","year":"2018","journal-title":"J Allergy Clin Immunol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e23931","DOI":"10.4161\/jkst.23931","article-title":"Transcriptional regulation by STAT1 and STAT2 in the interferon JAK-STAT pathway","volume":"2","author":"Au-Yeung","year":"2013","journal-title":"JAKSTAT."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1126\/science.8197455","article-title":"Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins","volume":"264","author":"Darnell","year":"1994","journal-title":"Science."},{"key":"B13","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1056\/NEJMra1202117","article-title":"JAKs and STATs in immunity, immunodeficiency, and cancer","volume":"368","author":"O'Shea","year":"2013","journal-title":"N Engl J Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"3966","DOI":"10.1073\/pnas.0501063102","article-title":"Implications of an antiparallel dimeric structure of nonphosphorylated STAT1 for the activation\u2013inactivation cycle","volume":"102","author":"Zhong","year":"2005","journal-title":"Proc Natl Acad Sci USA."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2834","DOI":"10.1002\/eji.201445344","article-title":"Gain-of-function STAT1 mutations impair STAT3 activity in patients with chronic mucocutaneous candidiasis (CMC)","volume":"45","author":"Zheng","year":"2015","journal-title":"Eur J Immunol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"9238","DOI":"10.1073\/pnas.0802130105","article-title":"Tyrosine phosphorylation regulates the partitioning of STAT1 between different dimer conformations","volume":"105","author":"Wenta","year":"2008","journal-title":"Proc Natl Acad Sci USA."},{"key":"B17","doi-asserted-by":"publisher","first-page":"3372","DOI":"10.1101\/gad.1485406","article-title":"Dephosphorylation of phosphotyrosine on STAT1 dimers requires extensive spatial reorientation of the monomers facilitated by the N-terminal domain","volume":"20","author":"Mertens","year":"2006","journal-title":"Genes Dev."},{"key":"B18","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1089\/jir.2005.25.749","article-title":"The p38 mitogen-activated protein kinase pathway in interferon signal transduction","volume":"25","author":"Katsoulidis","year":"2005","journal-title":"J Interferon Cytokine Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.cellsig.2006.09.003","article-title":"STAT1 as a key modulator of cell death","volume":"19","author":"Kim","year":"2007","journal-title":"Cell Signal."},{"key":"B20","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/S1074-7613(03)00322-4","article-title":"Phosphorylation of the Stat1 transactivation domain is required for full-fledged IFN-\u03b3-dependent innate immunity","volume":"19","author":"Varinou","year":"2003","journal-title":"Immunity."},{"key":"B21","doi-asserted-by":"publisher","first-page":"6240","DOI":"10.1074\/jbc.M116.753848","article-title":"Molecular mechanism and structural basis of gain-of-function of STAT1 caused by pathogenic R274Q mutation","volume":"292","author":"Fujiki","year":"2017","journal-title":"J Biol Chem."},{"key":"B22","doi-asserted-by":"publisher","first-page":"ofx202","DOI":"10.1093\/ofid\/ofx202","article-title":"Risks of ruxolitinib in STAT1 gain-of-function-associated severe fungal disease","volume":"4","author":"Zimmerman","year":"2017","journal-title":"Open Forum Infect Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.molimm.2019.07.008","article-title":"Identification of a distinct subset of disease-associated gain-of-function missense mutations in the STAT1 coiled-coil domain as system mutants","volume":"114","author":"Petersen","year":"2019","journal-title":"Mol Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.3389\/fimmu.2020.01114","article-title":"Live cell imaging demonstrates multiple routes toward a STAT1 gain-of-function phenotype","volume":"11","author":"Giovannozzi","year":"2020","journal-title":"Front Immunol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1038\/s41467-020-14948-z","article-title":"Regulation of the linear ubiquitination of STAT1 controls antiviral interferon signaling","volume":"11","author":"Zuo","year":"2020","journal-title":"Nat Commun."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41525-018-0063-6","article-title":"Two different STAT1 gain-of-function mutations lead to diverse IFN-\u03b3-mediated gene expression","volume":"3","author":"Ovadia","year":"2018","journal-title":"NPJ Genomic Medicine."},{"key":"B27","unstructured":"AndrewsS\n          FastQC: A Quality Control Tool for High Throughput Sequence Data2010"},{"key":"B28","unstructured":"AronestyE\n          ea-utils : Command-Line Tools for Processing Biological Sequencing Data2011"},{"key":"B29","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1093\/bioinformatics\/btp352","article-title":"The sequence alignment\/map format and SAMtools","volume":"25","author":"Li","year":"2009","journal-title":"Bioinformatics."},{"key":"B31","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1186\/s12859-019-2879-1","article-title":"pcaExplorer: an R\/Bioconductor package for interacting with RNA-seq principal components","volume":"20","author":"Marini","year":"2019","journal-title":"BMC Bioinformatics"},{"key":"B33","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1093\/nar\/gkg611","article-title":"Signal search analysis server","volume":"31","author":"Ambrosini","year":"2003","journal-title":"Nucleic Acids Res."},{"key":"B34","doi-asserted-by":"publisher","first-page":"D252","DOI":"10.1093\/nar\/gkx1106","article-title":"HOCOMOCO: towards a complete collection of transcription factor binding models for human and mouse via large-scale ChIP-Seq analysis","volume":"46","author":"Kulakovskiy","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/nmeth1068","article-title":"Genome-wide profiles of STAT1 DNA association using chromatin immunoprecipitation and massively parallel sequencing","volume":"4","author":"Robertson","year":"2007","journal-title":"Nat Methods."},{"key":"B36","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1186\/s12864-016-3288-8","article-title":"The ChIP-Seq tools and web server: a resource for analyzing ChIP-seq and other types of genomic data","volume":"17","author":"Ambrosini","year":"2016","journal-title":"BMC Genom."},{"key":"B37","doi-asserted-by":"publisher","first-page":"768","DOI":"10.3389\/fimmu.2019.00768","article-title":"Impaired STAT3-dependent upregulation of IL2R\u03b1 in B cells of a patient with a STAT1 gain-of-function mutation","volume":"10","author":"van Zelm","year":"2019","journal-title":"Front Immunol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1016\/j.jaci.2013.01.004","article-title":"Gain-of-function STAT1 mutations are associated with PD-L1 overexpression and a defect in B-cell survival","volume":"131","author":"Romberg","year":"2013","journal-title":"J Allergy Clin Immunol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"274","DOI":"10.3389\/fimmu.2017.00274","article-title":"A novel heterozygous mutation in the STAT1 SH2 domain causes chronic mucocutaneous candidiasis, atypically diverse infections, autoimmunity, and impaired cytokine regulation","volume":"8","author":"Meesilpavikkai","year":"2017","journal-title":"Front Immunol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"D92","DOI":"10.1093\/nar\/gku1111","article-title":"The eukaryotic promoter database: expansion of EPDnew and new promoter analysis tools","volume":"43","author":"Dreos","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"B41","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s10875-018-0519-6","article-title":"Utility of ruxolitinib in a child with chronic mucocutaneous candidiasis caused by a novel STAT1 gain-of-function mutation","volume":"38","author":"Bloomfield","year":"2018","journal-title":"J Clin Immunol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1007\/s12185-020-02860-7","article-title":"Ruxolitinib treatment of a patient with steroid-dependent severe autoimmunity due to STAT1 gain-of-function mutation","volume":"112","author":"Moriya","year":"2020","journal-title":"Int J Hematol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1093\/cid\/ciw020","article-title":"Ruxolitinib induces interleukin 17 and ameliorates chronic mucocutaneous candidiasis caused by STAT1 gain-of-function mutation","volume":"62","author":"M\u00f6ssner","year":"2016","journal-title":"Clin Infect Dis."},{"key":"B44","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12867-017-0084-1","article-title":"Properties of STAT1 and IRF1 enhancers and the influence of SNPs","volume":"18","author":"Abou El Hassan","year":"2017","journal-title":"BMC Mol Biol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/gtc.12316","article-title":"Distal regulatory element of the STAT1 gene potentially mediates positive feedback control of STAT1 expression","volume":"21","author":"Yuasa","year":"2016","journal-title":"Genes Cells."},{"key":"B46","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.immuni.2015.04.014","article-title":"Asymmetric action of STAT transcription factors drives transcriptional outputs and cytokine specificity","volume":"42","author":"Hirahara","year":"2015","journal-title":"Immunity."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.632997\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T20:21:59Z","timestamp":1613766119000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.632997\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,17]]},"references-count":46,"alternative-id":["10.3389\/fimmu.2021.632997"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.632997","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,17]]},"article-number":"632997"}}